Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome
NCT05819853 on ClinicalTrials.gov · last registry update 2026-08-31
A small phase 3 — 80 participants, against a typical 424. Due to report 1 February 2028, alongside 25 other tracked readouts that quarter. Primary outcome, as filed: Change in ovulation frequency before and after semaglutide in females with PCOS. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 3 November 2023 — 2 years so far. semaglutide is approved in the US, but not for pcos — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- RECRUITING
- Phase
- P3
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor type
- Other
- Enrollment
- 80
- Started
- 2023-11-03
- Primary completion
- 2028-02-01 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in ovulation frequency before and after semaglutide in females with PCOS
Conditions studied
PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries · Obese
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.